União Europeia - português - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - esclerose múltipla - imunossupressores - tratamento de pacientes adultos com formas recorrentes de esclerose múltipla (rms) com doença ativa definida por características clínicas ou de imagem. o tratamento de pacientes adultos com início primária progressiva esclerose múltipla (ppms) em termos de duração da doença e o nível de deficiência, com recursos de imagem característica de atividade inflamatória.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

produtos roche quÍmicos e farmacÊuticos s.a. - ocrelizumabe - imunossupressores seletivos

União Europeia - português - EMA (European Medicines Agency)

mylan ireland limited - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

União Europeia - português - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

União Europeia - português - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

União Europeia - português - EMA (European Medicines Agency)

teva gmbh - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

União Europeia - português - EMA (European Medicines Agency)

accord healthcare s.l.u. - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

novartis biociencias s.a - ofatumumabe - imunossupressores seletivos

União Europeia - português - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunossupressores - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - medicamentos para obstrutiva, doenças das vias respiratórias, - alérgica asthmaxolair é indicado em adultos, adolescentes e crianças (de 6 a.